Annual Report for Fiscal Year 2025 - This is Eli Lilly's Form 10-K annual report filed on February 12, 2026, covering the fiscal year ended December 31, 2025, disclosing comprehensive financial performance, business operations, and risk factors for the pharmaceutical preparations company. Financial Statements and XBRL Data - The filing contains standardized financial statements in XBRL format…

Our analysis rates this filing CAUTIOUS. Eli Lilly faces an ELEVATED concern environment driven by three material dynamics: (1) intensifying GLP-1 market competition from multiple well-capitalized competitors entering obesity/diabetes treatment space, directly threatening Mounjaro/Zepbound revenue…

Concern level: HIGH (6.8/10). Key factors: Three new high-severity risks identified with severity scores of 7/10 (GLP-1 market competition, patent expiration/biosimilar competition) representing material threats to core revenue streams; GLP-1 market competition risk elevated from standard competitive threat to material concern; Mounjaro/Zepbound face accelerating competitive pressure from Novo…

Notable risk changes: GLP-1 market competition intensifying with multiple new competitors entering obesity/diabetes treatment space; Mounjaro/Zepbound face pricing and market share pressure from Novo Nordisk, Amgen, and others; Patent expiration timeline for key products (Trulicity, Jardiance) approaching; biosimilar competition could materially reduce revenue from these mature blockbusters; Supply chain constraints…

The model predicts LLY will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.